Pembrolizumab plus lenvatinib (P plus L) versus alternative therapies in first-line (1L) advanced renal cell carcinoma (aRCC) by IMDC risk status: A network meta-analysis (NMA).

被引：0
|
作者：
Rane, Pratik
Yan, Kevin
Schmidinger, Manuela
Peer, Avivit
Druyts, Eric
Burgents, Joseph E.
Sundaram, Murali
机构：
[1] Merck & Co Inc, North Wales, PA USA
[2] Pharmalyt Grp, Vancouver, BC, Canada
[3] Med Univ Vienna, Comprehens Canc Ctr, Dept Urol, Vienna, Austria
[4] Rambam Hlth Care Campus, Haifa, Israel
[5] Merck & Co Inc, Rahway, NJ USA
[6] Merck Sharp & Dohme LLC, Rahway, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
281-5277-5597; 298-4770-10048-7646-2344; 6; 2; 3615; 137; 3581; 14; 3585; 3605; 171; 3583; 3; 1; 38092-18643;
D O I：
10.1200/JCO.2024.42.4_suppl.421
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：421 / 421
页数：1
相关论文
共 50 条
  • [21] Cost-Effectiveness of Lenvatinib Plus Pembrolizumab or Everolimus as First-Line Treatment of Advanced Renal Cell Carcinoma
    Wang, Ye
    Wang, Hao
    Yi, Manman
    Han, Zhou
    Li, Li
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [22] Lenvatinib plus Pembrolizumab as first-line treatment in patients with advanced renal cell carcinoma (aRCC) - real world data from a retrospective multi- center analysis
    Stelmach, Ramona
    Schlack, Katrin
    Muhle, Clemens
    Darr, Christopher
    Neuberger, Stephanie
    Reichert, Mathias
    Rehlinghaus, Marc
    Flegar, Luka
    Zengerling, Friedemann
    Casuscelli, Jozefina
    Cox, Alexander
    Nestler, Tim
    Egenolf, Timo
    Brehmer, Bernhard
    Vallet, Sonia
    Ivanyi, Philipp
    Neuberger, Manuel
    Paffenholz, Pia
    Grunwald, Viktor
    Zschabitz, Stefanie
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 88 - 88
  • [23] NETWORK META- ANALYSIS (NMA) OF IMMUNOONCOLOGY (IO) TREATMENTS FOR FIRST-LINE (1L) ADVANCED OR METASTATIC MELANOMA
    Thosar, M.
    Khankhel, Z.
    McDonald, L.
    Moshyk, A.
    Ejzykowicz, F.
    Najlerahim, S.
    Farouk, A.
    Toor, K.
    Chan, K.
    VALUE IN HEALTH, 2023, 26 (12) : S25 - S25
  • [24] Real-world effectiveness and safety of first-line (1L) avelumab plus axitinib in patients with advanced renal cell carcinoma (aRCC): Primary analysis of the AVION study.
    Merseburger, Axel Stuart
    Baklanova, Olga
    Garlonta, Victor T.
    Androulakis, Nikolaos E. M.
    Christopoulou, Athina
    Timotheadou, Eleni
    Demey, Wim
    Janssen, Jan
    Ivanyi, Philipp
    Brouwers, Barbara Anna Henk
    Wynendaele, Wim
    Wang, Lusha
    Kostkova, Lenka
    Hoffman, Jason
    Manzel, Arndt
    Koumarianou, Anna
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [25] Analyses on impact of tumor burden at progression and changes in IMDC from baseline in patients (pts) with advanced renal cell carcinoma (aRCC) treated with lenvatinib plus pembrolizumab (L plus P) in the phase 3 CLEAR trial.
    Keizman, Daniel
    Bedke, Jens
    Staehler, Michael D.
    Matveev, Vsevolod B.
    George, Saby
    Hutson, Thomas E.
    Vaishampayan, Ulka N.
    Merchan, Jaime R.
    Eto, Masatoshi
    Rha, Sun Young
    Waddell, Tom
    Sabbatini, Roberto
    Barthelemy, Philippe
    Burgents, Joseph E.
    Ren, Min
    Brown, Ian
    Saal, Hakim
    Choueiri, Toni K.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : 531 - 531
  • [26] Atezolizumab plus bevacizumab versus lenvatinib as first-line therapy for advanced hepatocellular carcinoma: A systematic review and meta-analysis
    Giri, Suprabhat
    Angadi, Sumaswi
    Vaidya, Arun
    Singh, Ankita
    Roy, Akash
    Sundaram, Sridhar
    CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2023, 9 (03) : 228 - 235
  • [27] Lenvatinib plus pembrolizumab as first-line therapy in patients with advanced renal cell carcinoma outside of clinical trials - results of a monocentric analysis
    Wullenkord, R.
    Heller, M.
    Ferber, D. S.
    Hoeper, C.
    Bochtler, T.
    Haag, G. M.
    Berger, A. K.
    Jaeger, D.
    Zschaebitz, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 320 - 321
  • [28] First-Line Lenvatinib Plus Pembrolizumab or Everolimus versus Sunitinib for Advanced Renal Cell Carcinoma: A United States-Based Cost-Effectiveness Analysis
    Zhu, Youwen
    Liu, Kun
    Ding, Dong
    Peng, Libo
    CLINICAL GENITOURINARY CANCER, 2023, 21 (03) : 417e1 - 417e10
  • [29] COMPARATIVE EFFICACY OF PEMBROLIZUMAB PLUS AXITINIB (P plus A) VERSUS FIRST-LINE SYSTEMIC THERAPIES FOR ELDERLY PATIENTS WITH ADVANCED/METASTATIC RCC (MRCC): A SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS
    McGovern, I
    Shirali, R.
    Simon, A.
    Zhong, Y.
    Perini, R.
    Lorenzi, M.
    Adejoro, O.
    VALUE IN HEALTH, 2019, 22 : S441 - S441
  • [30] A Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Versus Pembrolizumab Plus Axitinib and Versus Avelumab Plus Axitinib in First-Line Treatment of Advanced Renal Cell Carcinoma
    Shay, Rebecca
    Nicklawsky, Andrew
    Gao, Dexiang
    Lam, Elaine T.
    CLINICAL GENITOURINARY CANCER, 2021, 19 (04) : 370 - +
12345